#USA #pharmaceuticals #Deerfield #ESTEVE #TerSera

ESTEVE Expands Its Presence with Strategic Acquisition

In a significant move to broaden its footprint in the U.S. pharmaceutical market, ESTEVE has announced an agreement to acquire TerSera Therapeutics' Infusion Specialty Therapies Business Unit (IST). This acquisition, which reflects ESTEVE's continued commitment to addressing unmet medical needs, will add two specialized medications to their portfolio, namely Prialt® and Quzyttir®.

Details of the Acquisition

Under this agreement, ESTEVE will gain global rights to Quzyttir®, which is a breakthrough injectable second-generation H1 antihistamine, as well as consolidate its rights for Prialt®, an FDA-approved medication for the management of severe chronic pain.

Prialt® is particularly notable as the only non-opioid option available for patients who have not found relief through other treatments, providing a critical solution for chronic pain management. On the other side, Quzyttir® is pivotal for treating acute urticaria in both adults and children six months and older, marking a significant milestone in patient care for allergic conditions.

CEO Insights

Staffan Schüberg, the CEO of ESTEVE, expressed enthusiasm for welcoming the TerSera team, stating, "This acquisition perfectly aligns with our strategic vision of providing highly specialized solutions where there is a significant unmet medical need." This statement reinforces ESTEVE's mission to improve lives through the availability of advanced therapeutic options.

TerSera's CEO, Edward Donovan, also highlighted the symbiotic relationship that has developed over their longstanding partnership, particularly underlining that ESTEVE’s expertise made them the ideal candidate for continuing the momentum of Prialt® and Quzyttir®.

Strategic Importance

The transaction is set to close in the first quarter of 2026, pending necessary regulatory approvals. This acquisition not only enhances ESTEVE's offerings in specialized therapies but also accelerates their entry into the U.S. market, a crucial move as it represents the largest pharmaceutical market in the world.

ESTEVE's expansion narrative has been gaining traction since 2024, following its acquisition of a business focused on rare and ultra-rare diseases, further indicating a robust growth strategy. Their portfolio has significantly diversified with recent licenses for various biologic products targeting severe conditions in both adults and children, showcasing an ongoing commitment to tackling complex healthcare challenges.

Looking Ahead

As the landscape of pharmaceutical therapies continues to evolve rapidly, acquisitions like this will be crucial for companies looking to enhance their market presence and product offerings. For ESTEVE, the addition of Quzyttir® and the consolidation of Prialt® could lead to greater visibility and enhanced capabilities in the competitive U.S. market.

The financial dimensions of the acquisition are being managed by Perella Weinberg Partners, while legal advice is being provided by Arnold & Porter. The strategic foresight shown by both companies highlights an industry trend towards partnerships aimed at delivering innovative health solutions.

Conclusion

As ESTEVE and TerSera embark on this new chapter, stakeholders will be keenly watching the developments. This acquisition marks a pivotal milestone that emphasizes ESTEVE's commitment to expanding its specialized capabilities in healthcare, with a clear focus on delivering therapeutic innovations that address critical patient needs worldwide.